Birinapant

Unknown / undisclosed

Also known as TL32711

Stoppedregistry status

Evidence outlook

Phase 2 study terminated; a study outside Ovarian Cancer is active

The furthest-phase study registered for this program (NCT01681368) was terminated, and no Ovarian Cancer study is active; a study outside Ovarian Cancer is active on the registry. No evidence signal is assigned from a stopped study. Check the registry record for the sponsor's stated reason.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (3)
Ovarian Cancer
NCT01766622 · National Institutes of Health Clinical Center (CC)
2012-11-30 – 2013-07-24 · Ovarian Neoplasms, Ovarian Cancer, Fallopian Tube Neoplasms, Fallopian Tube Cancer
What this study did
Other / comorbidity
NCT02147873 · TetraLogic Pharmaceuticals
2014-06 – 2016-06 · Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
What this study did
Phase 1/2 (5)
Other / comorbidity
NCT02756130 · Jonsson Comprehensive Cancer Center
2018-08-01 – 2021-02-01 · High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
What this study did
NCT02587962 · Medivir
2017-08-04 – 2020-02-17 · Solid Tumors
What this study did
NCT01828346 · TetraLogic Pharmaceuticals
2013-06 – 2015-11 · Myelodysplastic Syndrome
What this study did
NCT01486784 · Abramson Cancer Center at Penn Medicine
2011-11 – 2015-04 · Acute Myelogenous Leukemia
What this study did
NCT01188499 · TetraLogic Pharmaceuticals
2010-10 – 2014-03 · Cancer
What this study did
Phase 1 (6)
Ovarian Cancer
NCT01940172 · TetraLogic Pharmaceuticals
2013-11 – 2015-12 · Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal Cancer, Relapsed Fallopian Tube Cancer
What this study did
Other / comorbidity
NCT03803774 · National Cancer Institute (NCI)
2019-09-25 – 2027-07-09 · Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Sinonasal Squamous Cell Carcinoma
What this study did
NCT04553692 · IGM Biosciences, Inc.
2020-09-23 – 2025-01-20 · Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
What this study did
NCT02288208 · TetraLogic Pharmaceuticals
2014-11 – 2015-05 · Hepatitis B
What this study did
NCT01573780 · Roswell Park Cancer Institute
2012-04 – 2013-09 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00993239 · TetraLogic Pharmaceuticals
2009-11 – 2013-03 · Cancer
What this study did

Competitive landscape

This drug's own stage for Ovarian Cancer: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Birinapant: this drugPhase 2—IAP (inhibitor of apoptosis) proteinsnot yet gradedNo reviewed efficacy summary in this indication
Avutometinib / Defactinib (Avmapki Fakzynja Co-Pack)ApprovedSmall moleculeMEK1/2 and RAF (CRAF, BRAF), FAKnot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)not yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Mirvetuximab Soravtansine (Elahere)ApprovedAntibody–drug conjugate—not yet gradedNo reviewed efficacy summary in this indication
NiraparibApprovedSmall moleculePARP1/2Reliable signal
NCT02655016: Progression Free Survival (Up to 34 months): Placebo 8.2 Months (95% CI 7.3 to 8.5) | Niraparib 13.8 Months (95% CI 11.5 to 14.9)
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Relacorilant (Lifyorli)ApprovedSmall moleculeGlucocorticoid receptorPartial signalNo reviewed efficacy summary in this indication
RucaparibApprovedSmall moleculePARP (poly ADP-ribose polymerase) enzymes, PARP1/2Reliable signalFeatured results are non-efficacy only in this race
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
DurvalumabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
GSK 5733584Phase 3——not yet gradedNo reviewed efficacy summary in this indication
INCB123667Phase 3Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Olvimulogene NanivacirepvecPhase 3Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
Raludotatug DeruxtecanPhase 3Antibody–drug conjugateCDH6 (Cadherin-6)not yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sofetabart MipitecanPhase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Torvutatug SamrotecanPhase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Ixotatug VedotinPhase 2Antibody–drug conjugateClaudin 6 (CLDN6)not yet gradedNo reviewed efficacy summary in this indication
StenoparibPhase 2Small moleculePARP1/2, Tankyrase 1/2not yet gradedNo reviewed efficacy summary in this indication
COM701Phase 1/2Monoclonal antibodyPVRIG (CD112R)not yet gradedNo reviewed efficacy summary in this indication
REGN5668Phase 1/2Multispecific antibodyMUC16 x CD28not yet gradedNo reviewed efficacy summary in this indication
RezatapoptPhase 1/2Small moleculep53 reactivatornot yet gradedNo reviewed efficacy summary in this indication
TUB-040Phase 1/2Antibody–drug conjugateNaPi2b (sodium-dependent phosphate transporter, SLC34A2)not yet gradedNo reviewed efficacy summary in this indication
UbamatamabPhase 1/2Monoclonal antibodyMUC16 x CD3not yet gradedNo reviewed efficacy summary in this indication
27T51Phase 1Cell therapyMUC16not yet gradedNo reviewed efficacy summary in this indication
ABBV-901Phase 1UndisclosedFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
APG-2449Phase 1Small moleculeFAK / ALK / ROS1not yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
IDE-161Phase 1Small moleculePARGnot yet gradedNo reviewed efficacy summary in this indication
XmAb541Phase 1Multispecific antibodyClaudin 6 (CLDN6) x CD3not yet gradedNo reviewed efficacy summary in this indication
Luveltamab TazevibulinDiscontinuedAntibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.